Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
47
NTR Quote, Financials, Valuation and Earnings
Last price:
$58.33
Seasonality move
:
5.7%
Day range:
$58.45 - $59.83
52-week range:
$43.70 - $65.08
Dividend yield:
3.71%
P/E ratio:
54.64x
P/S ratio:
1.12x
P/B ratio:
1.19x
Volume:
2.6M
Avg. volume:
2.1M
1-year change:
14.83%
Market cap:
$28.5B
Revenue:
$26B
EPS (TTM):
$1.07
Analysts' Opinion
-
Consensus RatingNutrien has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 11 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $64.19, Nutrien has an estimated upside of 9.81% from its current price of $58.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $52.00 representing 11.05% downside risk from its current price of $58.46.
Fair Value
-
According to the consensus of 22 analysts, Nutrien has 9.81% upside to fair value with a price target of $64.19 per share.
NTR vs. S&P 500
-
Over the past 5 trading days, Nutrien has underperformed the S&P 500 by -5.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nutrien does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nutrien revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Nutrien reported revenues of $5.1B.
Earnings Growth
-
Nutrien earnings have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Nutrien reported earnings per share of $0.02.
Enterprise value:
41B
EV / Invested capital:
--
Price / LTM sales:
1.12x
EV / EBIT:
24.39x
EV / Revenue:
1.60x
PEG ratio (5yr expected):
--
EV / Free cash flow:
48.84x
Price / Operating cash flow:
34.36x
Enterprise value / EBITDA:
10.18x
Gross Profit (TTM):
$7.3B
Return On Assets:
1%
Net Income Margin (TTM):
2.05%
Return On Equity:
2.13%
Return On Invested Capital:
1.42%
Operating Margin:
5.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $36.3B | $28.3B | $25.7B | $5.4B | $5.1B | |
| Gross Profit | $14.1B | $8.1B | $7.3B | $1.5B | $1.3B | |
| Operating Income | $9B | $3.5B | $2.7B | $504M | $291M | |
| EBITDA | $11.8B | $4.4B | $4B | $984M | $797M | |
| Diluted EPS | $12.74 | $1.71 | $1.07 | $0.32 | $0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.5B | $17B | $18.3B | $15.2B | $15.4B | |
| Total Assets | $47.9B | $53.3B | $56.6B | $53.6B | $53.1B | |
| Current Liabilities | $9.3B | $14.9B | $15.5B | $13.1B | $12.6B | |
| Total Liabilities | $25.6B | $28.7B | $31.3B | $28.6B | $29B | |
| Total Equity | $22.3B | $24.5B | $25.3B | $25B | $24.1B | |
| Total Debt | $10.3B | $11.1B | $14.1B | $12.3B | $13.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.3B | $5.4B | $2.9B | -$487M | -$1.1B | |
| Cash From Investing | -$3.1B | -$2.8B | -$1.9B | -$494M | -$243M | |
| Cash From Financing | -$3.2B | -$3.6B | -$636M | $548M | $1.4B | |
| Free Cash Flow | $4.7B | $2.9B | $839M | -$840M | -$1.4B | |
NTR
Sector
Market Cap
$28.5B
$19.1M
Price % of 52-Week High
89.83%
70.42%
Dividend Yield
3.71%
0%
Shareholder Yield
3.91%
0.73%
1-Year Price Total Return
14.83%
-6.33%
Beta (5-Year)
0.805
0.736
Dividend yield:
3.71%
Annualized payout:
$2.16
Payout ratio:
201.9%
Growth streak:
7 years
Technicals
8-day SMA
Sell
Level
$60.66
200-day SMA
Buy
Level
$52.06
Bollinger Bands (100)
Buy
Level
51.21 - 59.89
Chaikin Money Flow
Sell
Level
-3.3M
20-day SMA
Sell
Level
$60.10
Relative Strength Index (RSI14)
Sell
Level
42.05
ADX Line
Sell
Level
17.42
Williams %R
Neutral
Level
-77.8179
50-day SMA
Sell
Level
$59.35
MACD (12, 26)
Buy
Level
16.39
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4418)
Buy
CA Score
(Annual)
Level (-0.2289)
Buy
Beneish M-Score
(Annual)
Level (-2.772)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.565)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world’s largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Stock Forecast FAQ
In the current month, NTR has received 10 Buy ratings 11 Hold ratings, and 1 Sell ratings. The NTR average analyst price target in the past 3 months is $64.19.
-
Where Will Nutrien Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nutrien share price will rise to $64.19 per share over the next 12 months.
-
What Do Analysts Say About Nutrien?
Analysts are divided on their view about Nutrien share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nutrien is a Sell and believe this share price will drop from its current level to $52.00.
-
What Is Nutrien's Price Target?
The price target for Nutrien over the next 1-year time period is forecast to be $64.19 according to 22 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is NTR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nutrien is a Hold. 11 of 22 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NTR?
You can purchase shares of Nutrien via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nutrien shares.
-
What Is The Nutrien Share Price Today?
Nutrien was last trading at $58.33 per share. This represents the most recent stock quote for Nutrien. Yesterday, Nutrien closed at $58.46 per share.
-
How To Buy Nutrien Stock Online?
In order to purchase Nutrien stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
